VIENNA, June 1, 2023
/PRNewswire/ -- Croma-Pharma, a global player and challenger in the
dynamically growing, minimally invasive aesthetics market,
announces that it will launch Pliaglis®, a topical local
anaesthetic for superficial dermatological procedures, in its
European core markets including Germany, the United
Kingdom ("UK"), and Ireland. Further markets including
Brazil will follow by the end of
2023. The anaesthetic cream complements Croma's range of aesthetic
injectables, a key pillar of its comprehensive and innovative
aesthetics portfolio.
The launch is preceded by an exclusive licensing agreement for
Pliaglis® with Canadian dermatology company
Crescita Therapeutics Inc. ("Crescita"). The agreement grants Croma
the exclusive rights to commercialize Pliaglis in nine countries
including Germany, Ireland, Switzerland, Belgium, Luxembourg, the UK and Netherlands and Brazil.
"Pliaglis perfectly complements our range of aesthetic
injectables. It is a further essential building block in our
focused and differentiated aesthetics portfolio and proof of our
full dedication to medical aesthetics. The planned launch of
Pliaglis in our European markets and in Brazil in 2023 will further accelerate our
growth," commented Andreas Prinz,
CEO. "We are thrilled about our partnership with Crescita, together
bringing this therapeutic option to healthcare professionals in our
core markets."
Specifically designed and licensed for anaesthetic needs in
aesthetic medicine, Pliaglis® is applied by the
medical professional before a wide range of minimally invasive
aesthetic procedures such as dermal filler or laser treatments, to
provide effective and long-lasting local dermal anaesthesia to
protect the patient and minimise pain.**
*Pliaglis® is indicated in adults to produce local
dermal anaesthesia on intact skin prior to dermatological
procedures.
**About Pliaglis® Pliaglis is a
topical local anaesthetic cream that provides safe and effective
local dermal analgesia on intact skin prior to superficial
dermatological procedures. The formulation contains a eutectic
mixture of 7% lidocaine and 7% tetracaine that utilizes Crescita's
proprietary phase-changing topical cream Peel technology.
The Peel technology consists of a drug-containing cream
which, once applied to a patient's skin, dries to form a pliable
layer that releases drug into the skin. Pliaglis is applied to
intact skin for 20 to 30 minutes prior to superficial
dermatological procedures such as dermal filler injections,
non-ablative laser facial resurfacing, or pulsed-dye laser therapy
and 60 minutes prior to procedures such as laser-assisted tattoo
removal. Following the application period, the pliable layer is
easily removed from the skin allowing the procedure to be performed
with minimal to no pain. In clinical studies, the mean duration of
anesthesia has been shown to be in the range of 7 to 9 hours after
the application of Pliaglis.
About Croma
Croma is a global player in the minimally invasive aesthetics
market and a leading European manufacturer of premium quality
hyaluronic acid syringes. The company offers a comprehensive and
innovative aesthetics portfolio including botulinum toxin, fillers,
lifting threads and biostimulators complemented by its own skincare
brand. Founded in 1976 by a pharmacist couple,
Croma-Pharma® GmbH is a family company headquartered in
Austria where it also operates its
manufacturing plant. With 550 employees, 13 subsidiaries in
Europe and Brazil, two joint ventures and 60 exclusive
export partners, it distributes its products in 80 markets
globally, including the US/Canada,
China and Australia/New
Zealand. It also operates as a contract manufacturer in
orthopaedics and ophthalmology. For more information please visit
croma.at.
About Crescita Therapeutics Inc.
Crescita (TSX: CTX) (OTC US: CRRTF) is a growth-oriented,
innovation-driven Canadian commercial dermatology company with
in-house R&D and manufacturing capabilities. The Company offers
a portfolio of high-quality, science-based non-prescription
skincare products and early to commercial stage prescription
products. We also own multiple proprietary transdermal delivery
platforms that support the development of patented formulations to
facilitate the delivery of active ingredients into or through the
skin. For more information
visit, www.crescitatherapeutics.com.
PRPLIAb0423GMX
Logo -
https://mma.prnewswire.com/media/2044449/4030991/Croma_Pharma_Logo.jpg
Media contact:
Uschi Mayer
External Communications & PR
+43 676 84 68 68 966
uschi.mayer@croma.at
View original
content:https://www.prnewswire.com/news-releases/croma-pharma-launch-of-topical-anaesthetic-pliaglis-in-europe-301839776.html
SOURCE Croma-Pharma
